Cargando…

Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy?

BACKGROUND: Major pathologic response (MPR) is mainly focused on residual viable tumor in the tumor bed regardless of lymph node. Herein, we investigated the predictive value of MPR and node status on survival in nonsmall‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemotherapy (NAC) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Jing‐Sheng, Li, Shuo, Yan, Shu‐Mei, Yang, Jie, Yang, Mu‐Zi, Xie, Chu‐Long, Li, Ji‐Bin, Feng, Yan‐Fen, Yang, Hao‐Xian, Hou, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088941/ https://www.ncbi.nlm.nih.gov/pubmed/33751832 http://dx.doi.org/10.1111/1759-7714.13903

Ejemplares similares

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
por: Tfayli, Arafat, et al.
Publicado: (2020)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis
por: Chen, Yujia, et al.
Publicado: (2023)

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
por: Pataer, Apar, et al.
Publicado: (2018)

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy
por: Pataer, Apar, et al.
Publicado: (2022)

Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis: Erratum
Publicado: (2015)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection
por: Wu, Ching-Yang, et al.
Publicado: (2015)

Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
por: Chen, Yan, et al.
Publicado: (2018)

Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: He, Jiaxi, et al.
Publicado: (2015)

Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis
por: Xue, Ling Bo, et al.
Publicado: (2019)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Pathologic Correlation of Serum Carcinoembryonic Antigen and Cytokeratin 19 Fragment in Resected Nonsmall Cell Lung Cancer
por: Lee, Seokkee, et al.
Publicado: (2013)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer
por: Sandø, Alina Desiree, et al.
Publicado: (2023)

The optimal neoadjuvant regimen for nonsmall cell lung cancer: A meta-analysis
por: Liu, Yi, et al.
Publicado: (2022)

Utility of (18)F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non‑small cell lung cancer
por: Chen, Xiaowei, et al.
Publicado: (2023)

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015)

Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Zheng, Yi-Zi, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Pathological complete response to radical surgery after receiving durvalumab plus neoadjuvant chemotherapy for 1 limited-stage small cell lung cancer patient: a case report
por: Li, Zhifeng, et al.
Publicado: (2022)

Major pulmonary resection after neoadjuvant chemotherapy or chemoradiation in potentially resectable stage III non-small cell lung carcinoma
por: Peer, Michael, et al.
Publicado: (2021)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
por: Shi, Liang, et al.
Publicado: (2022)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Prognostic value of serum high‐density lipoprotein cholesterol elevation in nonsmall cell lung cancer patients receiving radical surgery
por: Luo, Fan, et al.
Publicado: (2020)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols
por: Li, Chia-Ying, et al.
Publicado: (2016)

FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer
por: Zhang, Shun, et al.
Publicado: (2020)

Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association
por: Mehta, Anurag, et al.
Publicado: (2019)

Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer
por: Ring, A E, et al.
Publicado: (2004)

Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer
por: Zhao, Fangyuan, et al.
Publicado: (2023)

Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
por: Zhu, Dexiang, et al.
Publicado: (2014)

Resection of colorectal liver metastases following neoadjuvant chemotherapy
por: Chiappa, A, et al.
Publicado: (2007)

Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection
por: He, Fang, et al.
Publicado: (2020)

Infectious Morbidity in Pediatric Patients Receiving Neoadjuvant Chemotherapy for Sarcoma
por: Willmer, Denise, et al.
Publicado: (2021)

Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer
por: Li, Yang, et al.
Publicado: (2018)

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
por: Cao, Rui, et al.
Publicado: (2019)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jton33l95jo4gl0nsfb3o7lde4